Last reviewed · How we verify
Placebo: Human albumin 2.5%
Human albumin 2.5% acts as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.
Human albumin 2.5% acts as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure. Used for Hypovolemia and shock (hemorrhagic, septic, or traumatic), Hypoproteinemia and edema management, Plasma volume expansion during major surgery or critical illness.
At a glance
| Generic name | Placebo: Human albumin 2.5% |
|---|---|
| Sponsor | Baxalta now part of Shire |
| Drug class | Plasma volume expander; colloid |
| Modality | Biologic |
| Therapeutic area | Critical Care; Hematology |
| Phase | FDA-approved |
Mechanism of action
Human albumin is a naturally occurring plasma protein that increases and maintains intravascular oncotic pressure, helping to retain fluid in the vascular space and prevent fluid shifts into the interstitium. It also serves as a carrier protein for various endogenous and exogenous substances. The 2.5% concentration is a hypotonic or isotonic formulation used for volume replacement in conditions involving significant fluid loss or hypoproteinemia.
Approved indications
- Hypovolemia and shock (hemorrhagic, septic, or traumatic)
- Hypoproteinemia and edema management
- Plasma volume expansion during major surgery or critical illness
Common side effects
- Hypervolemia
- Pulmonary edema
- Allergic reaction
- Fever
- Chills
Key clinical trials
- The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial (PHASE2)
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells (PHASE1)
- Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis (PHASE1, PHASE2)
- Non-specific Effects of Rabies Vaccine (PHASE4)
- GLASSIA Infusion Rate Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo: Human albumin 2.5% CI brief — competitive landscape report
- Placebo: Human albumin 2.5% updates RSS · CI watch RSS
- Baxalta now part of Shire portfolio CI